European Guidelines for Quality Assurance in Cervical Cancer Screening

Currently ca. 34,000 new cases and over 16,000 deaths due to cervical cancer are reported annually in the European Union Screening for cytological abnormalities and treatment of precursor lesions has contributed significantly to the substantial decline in cervical cancer incidence and mortality rates in Europe over recent decades. Improvements in the control of cervical cancer have been particularly discernible in those countries which have implemented population-based screening programmes with high acceptance of personal invitation. The current, expanded edition includes extensive updates on technical details and documentation, assessment of new technologies, as well as comprehensive instructions prepared by a multi-disciplinary team of experts for general practitioners, gynaecologists and cytopathologists.